Single Use Bioreactors Market Size, Share, and Trend Analysis, By Component (Bioreactor Systems, Media bags, Filtration assemblies, Others), By Volume (≤25 L, 26–250 L, 251–750 L, >750 L), By Cell Type (Mammalian Cells, Bacterial Cells, Yeast Cells, Others), By Application, By End-Use, and By Region, Forecast 2025-2032

Single Use Bioreactors Market Overview and Key Insights:

The global single-use bioreactors market size reached USD 4.17 billion in 2024 and is expected to register a revenue CAGR of 14.7% during the forecast period. Increasing adoption of bioreactors for media preparation, cell cultivation, process development, optimization, and microbial processes is driving market revenue growth.

Traditional bioreactors heavily rely on Cleaning-in-Place (CIP) and Sterilization-in-Place (SIP) procedures, which can be time-consuming and energy-intensive. In response, end-use industries are increasingly adopting single-use bioreactors to reduce sterilization time and costs, as well as lower maintenance expenses.

Market Drivers:

Biopharmaceutical manufacturers are increasingly using single-use technologies (SUTs) owing to the rising demand for biopharmaceutical products. Traditional stainless-steel methods have been limited, but these technologies offer numerous advantages and can be leveraged in various stages of the manufacturing process. A single-use bioreactor is a bioreactor with a disposable bag, allowing processors to use disposable technology in manufacturing processes. Single-use bioreactors are replacing conventional bioreactors in mammalian cell culture.

Single-use bioreactors offer numerous benefits over conventional systems, including reduced cleaning and sterilization demands, cost savings of over 60%, and easier qualification and validation procedures. They are particularly suitable for biopharmaceutical products and can quickly switch between processes, increasing productivity and reducing costs. They contain fewer parts and use more disposable material, reducing energy consumption and cleaning and sterilization.

Market Opportunity:

Rising usage of single-use bioreactors in research and development is expected to accelerate market revenue growth over the forecast period. Large molecule biopharmaceutical manufacturers are incorporating single-use technology in research and development. Alternative downstream processing techniques like Protein A alternatives and membrane filtration technology are emerging, potentially changing the industry.

Single-use bioreactors are replacing conventional bioreactors in mammalian cell culture. They are equipped with a disposable bag made of three-layer plastic foil, with one layer for mechanical stability, a second layer for gas barrier, and a contact layer for direct contact. Modifying single-use bioreactors for plant cell and tissue culture cultivation has led to new types and increased demand for safety-critical biopharmaceuticals.

Market Trends:

Advancement of integrated sensor technologies, particularly for critical parameters like pH, dissolved oxygen (DO), and biomass, is emerging as a major trend in the single-use bioreactors market. This sensor offers high-precision pH measurement with a simplified one-point calibration process, streamlining pre- and post-use validation. Its integration into disposable biocontainers supports broader adoption of real-time process control in SUB environments.

These advancements enable precise monitoring and control, helping manufacturers comply with GMP and QbD guidelines while improving operational efficiency. The combined use of this pH sensor with single-use mixers highlights the potential for fully integrated, closed-loop bioprocessing systems. This evolution supports the long-term industry vision of a fully disposable, automated biomanufacturing facility, reducing cross-contamination risks and setup times while enhancing scalability.

Restraints & Challenges:

Single-use bioreactors face limitations in oxygen transfer due to their delicate nature, which can be influenced by higher energy input. These systems can only hold up to 1000 L of volume, making scale-up limited. However, some suppliers are now offering units at 2,000 L and offering a range of bioreactors from bench-top to full-scale production. Challenges for adoption include higher-quality, lower-cost disposable bags and containers, reusable sensors and probes, and a full scale-up of the bioprocess.

Several key competitors are working on improving these aspects. Also, Cell culture processes using single-use bioreactors are challenging due to the closed, pre-sterilized system and the need for sensors for temperature, conductivity, glucose, oxygen, or pressure. This results in the inability to use pH-electrodes and calibration.

Component Segment Insights and Analysis:

Based on the Component, the Single-Use Bioreactors Market is segmented into Single-Use Bioreactor Systems, Single-Use Media Bags, Single-Use Filtration Assemblies, and Others.

Single-Use Bioreactor System contributed the largest revenue share in 2024. The market for single-use systems (SUSs) in the biopharmaceutical industry has grown. Next-generation vaccines will be produced using recombinant organisms and Single-Use Systems (SUSs) to increase production capacities and reduce costs. SUSs designs respond to changing needs for vaccine manufacturing, cell production, vectors, recombinant proteins, antibodies, and secondary metabolites. The pandemic has increased the demand for single-use systems in biopharmaceutical production, especially for protein production from mammalian cell cultures.

A two-chamber bioreactor is introduced, offering flexibility, ease of operation, and cost savings. The prototype aims to reduce factory footprint and contamination risk during culture transfer. The SARS-CoV-2 pandemic has prompted significant changes in the biopharmaceutical industry, including the development of candidate vaccines, therapies, equipment, and diagnostics. Global resource mobilization will bring single-use systems, process intensification, greater automation, and biosecurity. These changes will contribute to the rapid development and production of candidate vaccines, therapies, equipment, and diagnostics simultaneously.

Application Segment Insights and Analysis:

Based on the Application, the Single Use Bioreactors Market is segmented into Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell Therapy Products, Gene Therapy Vectors, Biosimilars, Enzymes, and Others.

The Cell Therapy Products segment is expected to register significant revenue growth by 2032. Advancements in autologous and allogeneic cell therapies, particularly CAR-T and stem cell-based products, are accelerating clinical and commercial adoption. Single-use bioreactors play a critical role in this growth by enabling closed, sterile, and scalable manufacturing systems essential for high-value, small-batch production.

Single-use bioreactors are used to test variables before scaling up to larger scales. They predict larger performance and are cost-effective. The bioreactor process development was divided into two phases: Phase I focused on Lentiviral Production Cells for faster growth and higher transfection efficiency, and Phase II tested lentivirus production in CD Prototype I. Factors like pH, agitation rate, dissolved oxygen concentration, and gas sparger options affect cellular productivity and viral vector stability.

End-Use Segment Insights and Analysis:

Based on the End-Use, the Single Use Bioreactors Market is segmented into Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), Contract Development and Manufacturing Organizations (CDMOs), Pharmaceuticals and Biotechnology, and Academic & Research Institutes.

Contract Manufacturing Organization (CMO) segment contributed a significant revenue share in 2024. The CMO industry has seen a shift towards flexible single-use bioreactors due to increased biologic pipelines and smaller quantities. This disposable plastic equipment can be started faster and produces the same quality as stainless-steel reactors.  The adoption of Single-Use System (SUS) devices in the industry varies by stage of manufacture. According to research, SUS bioreactors are used by 71.2% in process development but only 36% in commercial production.

However, over 55% use single-use sampling systems in clinical or commercial production, compared to 28% in R&D. The industry is making these decisions due to the cost savings of using disposable devices. As new products are developed using SUS, the market for single-use devices is expected to increase, with more scaling-out using multiple process lines anchored by large bioreactors. SUS devices are widely used in the bioprocessing industry, with 85% of operations using some at clinical or process development scale, including disposable filter cartridges and bioreactors.

The study compares contract manufacturing organizations (CMOs) use of single-use devices (SUS) and their need for flexible production capacity and fast campaign changeovers. CMOs use more diverse single-use components and systems, leading to greater penetration and rapid uptake of new SUS technologies. However, CMOs execute more development projects with smaller footprint requirements for higher revenue.

Geographical Outlook:

The Single Use Bioreactors Market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamics. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different regions and countries.

North America Single-Use Bioreactors Market:

North America registered the highest market revenue share in the Single Use Bioreactors Market. Growing demand for clinical trials and regulatory-approved novel drug therapy is driving the demand for the single-use bioreactors market in the U.S.  Single-use bioreactors are highly essential for regulatory-approved novel drug therapies due to their reduced contamination risk, faster turnaround, and compliance with the U.S. FDA standards. These bioreactors are useful for flexible, closed-system manufacturing, gene and mRNA-based therapies under strict regulatory controls. In 2023, the FDA’s Center for Drug Evaluation and Research (CDER) approved 55 novel drugs.

Moreover, the market growth in the single-use bioreactors industry is being driven by established pharmaceutical and biotechnology industries, cost and time savings, and the adoption of single-use technologies and major players in the region. Companies are developing next-generation bioreactors to improve efficiency, reduce costs, and increase production capacity.

For instance, on 11^th April 2024, FUJIFILM Corporation announced a USD 1.2 billion investment to enhance its large-scale cell culture CDMO business, to expand its FUJIFILM Diosynth Biotechnologies end-to-end biomanufacturing site in Holly Springs, North Carolina. This brings the total committed investment in the facility to more than USD 3.2 billion.

Asia Pacific Single-Use Bioreactors Market:

Asia Pacific is expected to register the fastest revenue growth, reaching 19.3% by 2032. Rising local demand for pharmaceutical production and export is supporting revenue growth in this region. This surge is prompting greater investment in infrastructure and advanced technologies.

Major Contract Development and Manufacturing Organizations (CDMOs) in this region, such as Samsung Biologics and AGC Biologics, are expanding their presence by investing in facilities across countries in the Asia Pacific. These efforts are significantly fueling the adoption of single-use bioreactors to support flexible, scalable, and cost-efficient next-generation biomanufacturing.

For instance, on 8^th April 2025, AGC Biologics announced a strategic move to adopt large-scale single-use technology at its upcoming facility in Yokohama, Japan. The site will feature two 5,000L Thermo Scientific DynaDrive Single-Use Bioreactors. Furthermore, 24^th April 2024, Samsung Biologics invested USD 1.47 billion to expand its bioreactor capacity, adding 180,000 liters and bringing the total production capacity to 784,000 liters. 

Europe Single Use Bioreactors Market:

Europe contributed a substantial revenue share in 2024. Rising usage of single-use bioreactors in medical applications is contributing to revenue share. Pharmaceutical products in the EU undergo conformity assessment to meet legal requirements by the European Medicines Agency. For instance, on 13^th April 2023, UKRI partners have announced new feasibility awards for sustainable biomanufacturing in the UK.

The joint investment by BBSRC, EPSRC, and Innovate UK will support 34 feasibility studies across the country. The awards aim to enhance UK global competitiveness by supporting research and innovation in developing new sustainable biomanufacturing products and processes by 2050. A USD 14.71 million funding opportunity is now open for collaborative projects.

Competition Analysis:

The Single Use Bioreactors Market is characterized by numerous players, with major players competing across segments and regions. The list of major players included in the Single Use Bioreactors Market report are:

• Thermo Fisher Scientific Inc. (U.S.)
• Cytiva (U.S.)
• Merck KGaA (Germany)
• WuXi Biologics (China)
• Sartorius AG (Germany)
• Eppendorf SE (Germany)
• Distek, Inc. (U.S.)
• PBS Biotech, Inc. (U.S.)
• Getinge AB (Sweden)
• ABEC (U.S.)
• Meissner Corporation (U.S.)
• Cellexus (U.K.)
• Infors AG (Switzerland)
• Adolf Kühner AG (Switzerland)
• Solida Biotech GmbH (Germany)

Strategic Developments in Single Use Bioreactors Market:

• On 25^th March 2025, Cytiva has expanded its Xcellerex X-platform to now include 500L and 2,000L single-use bioreactors. This new single-use bio-reactors enables researchers and process developers to scale seamlessly from 50L to 2,000L, to support the increasing needs of clinical development and commercial production. Cytiva aims to empower biomanufacturers to streamline scale-up and improve overall process efficiency.
• On 5^th June 2024, WuXi Biologics announced the successful installation of three 5,000L single-use bioreactors in the second drug substance production line at its Hangzhou-based facility, MFG20. The addition of these GMP-compliant bioreactors increases the facility’s total production capacity from 8,000L to 23,000L, significantly strengthening WuXi Biologics’ global manufacturing capabilities.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights of The Single Use Bioreactors Market Report:

The Single Use Bioreactors Market report offers a detailed analysis of market size, including historical revenue (in USD Billion) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Components Outlook (Revenue, USD Billion; 2022-2032)
  • Single-Use Bioreactor Systems
    • Stirred-Tank Bioreactors
    • Wave-Induced Bioreactors
    • Bubble Column Bioreactors
    • Others
  • Single-use media bags
    • 2D Bags
    • 3D Bags
  • Single-use filtration assemblies
  • Others

• Volume Outlook (Revenue, USD Billion; 2022-2032)
  • ≤25 L
  • 26–250 L
  • 251–750 L
  • >750 L

• Cell Type Outlook (Revenue, USD Billion; 2022-2032)
  • Mammalian Cells
  • Bacterial Cells
  • Yeast Cells
  • Plant Cells
  • Others

• Application Outlook (Revenue, USD Billion; 2022-2032)
  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Cell Therapy Products
  • Gene Therapy Vectors
  • Biosimilars
  • Enzymes
  • Others

• End-Use Outlook (Revenue, USD Billion; 2022-2032)
  • Contract Research Organizations (CROs)
  • Contract Manufacturing Organization (CMO)
  • Contract Development and Manufacturing Organizations (CDMOs)
  • Pharmaceuticals and Biotechnology
  • Academic & Research Institutes

• Regional Outlook (Revenue, USD Billion; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Singapore
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) About the Single Use Bioreactors Market Report